The patients who end up here
You had a virus two years ago and never came all the way back. Or an Epstein-Barr reactivation that your labs half-confirm and nobody wants to treat. Or a Lyme diagnosis, a course of antibiotics, and symptoms that outlasted the treatment by years. Or an autoimmune condition managed with drugs that control the numbers without giving you your life back.
Stem cell derived exosomes are produced by mesenchymal and adipose-derived stem cells but contain no living cells — only the signaling vesicles those cells release. Venturis Clinic administers a purchased allograft exosome product; no tissue is harvested at the clinic.
What these have in common is an immune system that stayed switched on after the thing that switched it on was gone. That is the category where stem cell derived exosome therapy is drawing the most serious research attention, and it is the reason most of our exosome patients come to us.
What exosomes actually are
Exosomes are extracellular vesicles — very small membrane-bound packets, roughly 30 to 150 nanometers across, that cells release to communicate with other cells. They carry proteins, lipids, and genetic material, and they act as signaling packages.
The important distinction: exosomes contain no living cells. Nothing in them divides, differentiates, or takes up residence. They are the message, not the messenger.
That difference matters for the immune conditions above, because the therapeutic target is not tissue replacement — it is signaling. An immune system that is over-responding is a communication problem, and exosomes are communication.
Venturis Clinic provides exosome therapy and other acellular treatments. We do not perform live-cell or viable stem cell transplantation. If you are specifically seeking live-cell transplantation, we are not your clinic, and it is better that you know now.
What the clinical research shows
Exosome research has moved quickly. A 2026 analysis of 90 human clinical trials found the most developed evidence in respiratory, immune, and inflammatory conditions — the same territory as post-viral syndromes. Source
Safety is the most established finding. Across the published trial base, the safety record has been consistently favorable:
- A Phase 2 randomized, placebo-controlled multicenter trial across five U.S. sites, enrolling 102 patients with COVID-related moderate-to-severe respiratory failure, reported no treatment-related adverse events. Among patients receiving the higher dose, mortality analysis favored treatment, with significantly improved ventilation-free days in the under-65 group. Source
- A Phase 1 trial of 24 healthy volunteers receiving nebulized exosomes found all participants tolerated administration well, with no adverse reactions in the following week. Source
The inflammatory-marker data is where post-viral patients should pay attention. In an open-label COVID study, treated patients showed an 83% survival rate with approximately 71% achieving clinical improvement, alongside substantial drops in the markers that track systemic inflammation — C-reactive protein down 77% and ferritin down 43%. Source
Those two markers are the ones that stay stubbornly elevated in many long COVID and post-viral presentations. A therapy that moves them is worth studying seriously, which is what is now happening across a growing trial base spanning kidney disease, respiratory conditions, neurological disorders, graft-versus-host disease, and autoimmune conditions.
This is an active and early field. Exosome therapy is investigational, and we will tell you exactly where the research stands for your specific situation before you decide anything.
Epstein-Barr and immune dysregulation
Epstein-Barr virus infects most adults at some point. For most people it causes nothing worse than a bout of mononucleosis, if that. But research increasingly links EBV to autoimmune conditions including multiple sclerosis, systemic lupus erythematosus, chronic fatigue presentations, and autoimmune thyroid disease.
The proposed mechanisms are molecular mimicry — EBV proteins resembling human proteins closely enough to trigger cross-reactive antibodies — and persistent B-cell activation driving ongoing inflammation long after the acute infection.
If that is the mechanism, then the therapeutic question is not how to kill a virus that is no longer replicating. It is how to modulate an immune response that has not stood down. That reframing is why immune-signaling approaches are being investigated here at all.
More on our Epstein-Barr virus page.
Chronic Lyme and post-treatment symptoms
Some patients complete a full course of antibiotics for Lyme disease and recover completely. Others do not, and continue with fatigue, cognitive difficulty, joint pain, and neurological symptoms for months or years.
Whatever the underlying explanation — and it remains genuinely debated — the persistent symptom pattern shares features with other post-infectious syndromes: chronic inflammatory activation and immune dysregulation. Patients in this group are frequently told there is nothing further to offer them. We think the immune-modulation question is worth exploring properly rather than dismissing.
Long COVID
The largest post-viral population in a generation, and the one driving most of the current research funding.
Long COVID presents with fatigue that does not respond to rest, post-exertional worsening, cognitive fog, autonomic dysfunction, and persistent inflammatory markers. The overlap with the EBV and post-Lyme presentations above is substantial enough that many researchers now treat them as related problems.
This is also where the exosome respiratory and inflammatory data is most directly relevant, and where our own broader program has the most depth. See our long COVID and post-viral support page, which covers how exosome therapy fits alongside EBOO and ozone in a combined approach.
How exosome therapy fits with the rest of what we do
We rarely use exosome therapy in isolation for these conditions. The program is usually built from several parts:
- EBOO and ozone therapy — extracorporeal blood oxygenation and ozonation, addressing systemic oxidative and inflammatory load
- Intravenous laser therapy using the Weber Medical system, delivering light directly into the bloodstream
- Exosome therapy, where evaluation supports it
- IV nutrient and NAD+ protocols to support cellular energy production
- Functional workup — the labs that explain why one patient responds and another does not
Which components apply, and in what order, is decided at evaluation rather than sold as a package.
What a course of treatment involves
Consultation and evaluation. History, examination, and review of your existing labs and imaging. For out-of-state patients this happens by telemedicine.
Eligibility screening. Bloodwork and, where relevant, imaging. We can order these to be completed at a laboratory or imaging facility near your home.
Preparation. Exosome product is sourced and handled to documented standards, with a certificate of analysis available on request. Ask for it here and at any other clinic.
Administration. Route and dose depend on the indication and are discussed in advance.
Follow-up. Reassessment against the markers and symptoms we identified at baseline, so that “did this help” is answered with data rather than impression.
Who is a good candidate
Generally suitable: adults with a documented post-viral or autoimmune presentation, stable enough for outpatient treatment, who have exhausted or declined conventional options, and who understand the treatment is investigational.
Generally not suitable: active malignancy, active untreated infection, pregnancy, significant uncontrolled organ dysfunction, or anyone seeking a guaranteed outcome. We would rather decline than take money from someone we cannot realistically help.
Factors that affect results: how long symptoms have been present, baseline inflammatory burden, sleep and metabolic health, and whether the underlying driver has actually been identified. This is why we run the workup first.
Cost and practical planning
We are direct-pay. Exact pricing depends on the protocol and is given in writing before anything is scheduled — no treatment begins without you knowing the total.
Budget for the whole program rather than a single item: consultation, laboratory work, the therapy itself, any adjunct treatments, and follow-up. Many patients use HSA or FSA funds; check your plan’s rules, as eligibility varies. Financing options are available.
Insurance does not cover investigational regenerative therapy. Assume it will not and plan accordingly.
Coming from out of state
A substantial share of our post-viral patients travel to us, and the schedule is built around that.
- Telemedicine consultation first. The initial workup happens remotely, including ordering bloodwork and imaging you complete near home. You arrive with results already in hand.
- Three to four days on the ground. Evaluation and treatment are compressed into one trip.
- Weekends are available for out-of-town patients, so a visit need not cost a working week.
- Twenty minutes from Will Rogers World Airport, with lodging nearby.
Call (405) 848-7246 before booking flights and we will map the schedule to your treatment plan.
How to evaluate any clinic offering this
Including us:
- Are you receiving a cell-free product or living cells? Get a direct answer.
- What is the source material, and can you see the certificate of analysis?
- What is the dose, the route, and the schedule?
- What markers will be measured before and after?
- What would make you a poor candidate — and has anyone told you that you might be?
- Who performs the procedure, and what are their credentials?
- Is the pricing given in full, in writing, before you commit?
A clinic that answers all seven clearly is a clinic taking the work seriously.
Contact
Venturis Clinic · 7917 N May Ave Suite B, Oklahoma City, OK 73120 · (405) 848-7246
Mon–Thu 9:00 AM–12:00 PM and 2:00 PM–6:00 PM. By appointment only.
Exosome therapy is investigational and is not approved or licensed by the U.S. Food and Drug Administration for the treatment, cure, mitigation, or prevention of any disease. There is currently no FDA-approved exosome product. Nothing on this page is a claim of efficacy, and no outcome is promised or implied. Individual results vary. This page is for general education, does not constitute medical advice, diagnosis or treatment, and does not establish a doctor–patient relationship. Exosome therapy is offered only following individual evaluation, is not appropriate for everyone, and is not a substitute for established medical care.
Venturis Clinic provides exosome therapy and other acellular regenerative treatments. We do not perform live-cell or viable stem cell transplantation. PRP injections at Venturis Clinic are performed by Don Guthrie, PA.
Alvin Philipose, DC, ICCP — Doctor of Chiropractic licensed in the State of Oklahoma.
Reviewed 22 August 2026. Sources linked inline.
